SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Nuvectis Reports Positive Phase 1b NXP200 Study Data

Nuvectis reported durable responses, including complete responses, in patients with BRAF V600-mutated recurrent or progressive gliomas in its NXP200 Phase 1b study.

NVCT

Related stories